Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations

Neurology

Volumn 47, Issue 3, 1996, Pages 785-788

  Inzelberg, R ^a,b,c   Nisipeanu, P ^a,b,c   Rabey, J M ^a,b,c   Orlov, E ^a,b,c   Catz, T ^a,b,c   Kippervasser, S ^a,b,c   Schechtman, E ^a,b,c   Korczyn, A D ^a,b,c  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE;

ADULT; AGED; ARTICLE; BRADYKINESIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DYSKINESIA; HUMAN; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; SCORING SYSTEM;

EID: 0029839676     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.3.785     Document Type: Article

References (14)

1. Chase TN, Mouradian MM, Engber TM. Motor response complications and the function of striatal efferent systems. Neurology 1993;43(suppl 6):S23-S27.
2. Korczyn AD. Pathophysiology of drug-induced dyskinesias. Neuropharmacology 1972;11:601-607.
3. Cederbaum JM. Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease. Neurol Clin N Am 1990;8:31-49.
4. Lewitt PA. Levodopa therapeutics. Neurology 1993;43(suppl 6):S31-S37.
5. Lewitt PA, Ward CD, Larsen TA, et al. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology 1983;33:1009-1014.
6. Rabey JM, Nisipeanu P, Inzelberg R, Korczyn AD. Beneficial effect of cabergoline, new long-lasting D2 agonist in the treatment of Parkinson's disease. Clin Neuropharmacol 1994;17: 286-293.
7. Hutton JT, Morris JL, Brewer MA. Controlled study of antiparkinsonian activity and tolerability of cabergoline. Neurology 1993;43:613-616.
8. Liebcrman A, Imke S, Muenter M, et al. Multicenter study of cabergolino, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa. Neurology 1993;43:1981-1984.
9. Lera G, Vaamonde J, Rodriguez M, Obeso JA. Cabergoline in Parkinson's disease: long-term follow-up. Neurology 1993;42: 2587-2590.
10. Jori ME, Francheshi M, Giusti MC, et al. Clinical experience with cabergoline, a new ergoline derivative in the treatment of Parkinson's disease. Adv Neurol 1990;53:539-543.
11. Ahlskog JE, Muenter MD, Moraganore DM, et al. Fluctuating Parkinson's disease: treatment with the long-acting dopamine agonist cabergoline. Arch Neurol 1994;51:1236-1241.
12. Inzelberg R, Nisipeanu P, Rabcy JM, Korczyn AD. Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist in Parkinson's disease. Mov Disord 1995;10: 604-607.
13. Fahn S, Elton RL, members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent developments in Parkinson's disease, vol II. Florham Park, NJ: Macmillan Healthcare Information, 1987:153-163, 293-304.
14. Korczyn AD. Biases in drug studies in Parkinson's disease. In: CF Rose, ed. Parkinson's disease and problems of clinical trials. London: Smith-Gordon, 1992:37-42.